UPDATE – Galectin Therapeutics Reports Financial Resu

NORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin...

Related Keywords

United States , American , Richarde Uihlein , Benjamins Carson , Joel Lewis , Jack Callicutt , Pol Boudes , Galectin Therapeutics Inc , International Study Evaluating The Efficacy , Company Contact , Exchange Commission , Drug Administration , Company Annual Report On Form , Company Quarterly Report On Form , American Association Of Liver Diseases Meeting , Nasdaq , Quarterly Report , Chief Executive Officer , Galectin Therapeutics , Board Chairman , Chief Medical Officer , American Association , Liver Diseases Meeting , Seamless Adaptive Phase , Placebo Controlled Multicenter , International Study Evaluating , Esophageal Varices , Company Sponsored Phase , Fatty Liver Disease , Advanced Fibrosis , Fast Track , Private Securities Litigation Reform Act , Annual Report , Chief Financial , Galectin Therapeutic , Consolidated Statements , Nasdaq Galt ,